CHCWM – Cancer & Hematology Centers of West Michigan

PAL-E602-001 (Palleon)

Description:  A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Cancers

Mechanism of Action:  cleaves off immunosuppressive sialoglycans from immune and tumor cells to enhance antitumor immunity

Target Patient Population:   Melanoma, Ovarian, Non Small Cell Lung Cancer, Colorectal and Pancreatic cancers

Study Design:  Drug is given IV weekly.